Disanto Giulio, Barro Christian, Benkert Pascal, Naegelin Yvonne, Schädelin Sabine, Giardiello Antonella, Zecca Chiara, Blennow Kaj, Zetterberg Henrik, Leppert David, Kappos Ludwig, Gobbi Claudio, Kuhle Jens
Neurocenter of Southern Switzerland, Civic Hospital, Lugano, Switzerland.
Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954.
Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the cerebrospinal fluid (CSF), and are detectable at low concentrations in peripheral blood. Various diseases causing neuronal damage have resulted in elevated CSF concentrations. We explored the value of an ultrasensitive single-molecule array (Simoa) serum NfL (sNfL) assay in multiple sclerosis (MS).
sNfL levels were measured in healthy controls (HC, n = 254) and two independent MS cohorts: (1) cross-sectional with paired serum and CSF samples (n = 142), and (2) longitudinal with repeated serum sampling (n = 246, median follow-up = 3.1 years, interquartile range [IQR] = 2.0-4.0). We assessed their relation to concurrent clinical, imaging, and treatment parameters and to future clinical outcomes.
sNfL levels were higher in both MS cohorts than in HC (p < 0.001). We found a strong association between CSF NfL and sNfL (β = 0.589, p < 0.001). Patients with either brain or spinal (43.4pg/ml, IQR = 25.2-65.3) or both brain and spinal gadolinium-enhancing lesions (62.5pg/ml, IQR = 42.7-71.4) had higher sNfL than those without (29.6pg/ml, IQR = 20.9-41.8; β = 1.461, p = 0.005 and β = 1.902, p = 0.002, respectively). sNfL was independently associated with Expanded Disability Status Scale (EDSS) assessments (β = 1.105, p < 0.001) and presence of relapses (β = 1.430, p < 0.001). sNfL levels were lower under disease-modifying treatment (β = 0.818, p = 0.003). Patients with sNfL levels above the 80th, 90th, 95th, 97.5th, and 99th HC-based percentiles had higher risk of relapses (97.5th percentile: incidence rate ratio = 1.94, 95% confidence interval [CI] = 1.21-3.10, p = 0.006) and EDSS worsening (97.5th percentile: OR = 2.41, 95% CI = 1.07-5.42, p = 0.034).
These results support the value of sNfL as a sensitive and clinically meaningful blood biomarker to monitor tissue damage and the effects of therapies in MS. Ann Neurol 2017;81:857-870.
神经丝轻链(NfL)是神经元细胞所特有的,会释放到脑脊液(CSF)中,并且在周围血液中能以低浓度被检测到。各种导致神经元损伤的疾病都会使脑脊液浓度升高。我们探讨了超灵敏单分子阵列(Simoa)血清NfL(sNfL)检测在多发性硬化症(MS)中的价值。
在健康对照者(HC,n = 254)和两个独立的MS队列中测量sNfL水平:(1)横断面研究,伴有配对的血清和脑脊液样本(n = 142),以及(2)纵向研究,进行重复血清采样(n = 246,中位随访时间 = 3.1年,四分位间距[IQR] = 2.0 - 4.0)。我们评估了它们与同时期的临床、影像学和治疗参数以及未来临床结局的关系。
两个MS队列中的sNfL水平均高于HC(p < 0.001)。我们发现脑脊液NfL与sNfL之间存在强关联(β = 0.589,p < 0.001)。有脑部或脊髓钆增强病灶(43.4pg/ml,IQR = 25.2 - 65.3)或脑部和脊髓均有钆增强病灶(62.5pg/ml,IQR = 42.7 - 71.4)的患者,其sNfL水平高于无此类病灶的患者(29.6pg/ml,IQR = 20.9 - 41.8;β = 1.461,p = 0.005和β = 1.902,p = 0.002)。sNfL与扩展残疾状态量表(EDSS)评估(β = 1.105,p < 0.001)和复发情况(β = 1.430,p < 0.001)独立相关。在疾病修饰治疗下,sNfL水平较低(β =